Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Net Cash Flow: 2020-2025

Historic Net Cash Flow for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Sep 2025 value amounting to -$25.5 million.

  • Arcutis Biotherapeutics' Net Cash Flow fell 150.56% to -$25.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$87.9 million, marking a year-over-year decrease of 425.55%. This contributed to the annual value of -$17.1 million for FY2024, which is 149.67% down from last year.
  • Arcutis Biotherapeutics' Net Cash Flow amounted to -$25.5 million in Q3 2025, which was down 233.45% from $19.1 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' Net Cash Flow's 5-year high stood at $223.6 million during Q1 2021, with a 5-year trough of -$199.6 million in Q2 2021.
  • Its 3-year average for Net Cash Flow is -$661,000, with a median of $2.4 million in 2023.
  • Per our database at Business Quant, Arcutis Biotherapeutics' Net Cash Flow crashed by 931.49% in 2021 and then surged by 1,975.78% in 2024.
  • Over the past 5 years, Arcutis Biotherapeutics' Net Cash Flow (Quarterly) stood at $44.7 million in 2021, then crashed by 162.46% to -$27.9 million in 2022, then skyrocketed by 31.40% to -$19.1 million in 2023, then crashed by 230.61% to -$63.3 million in 2024, then plummeted by 150.56% to -$25.5 million in 2025.
  • Its Net Cash Flow stands at -$25.5 million for Q3 2025, versus $19.1 million for Q2 2025 and -$18.2 million for Q1 2025.